Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genius Sports

Viad Corp

Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).

3 Stocks Worth a Watch for Solid Earnings Acceleration

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel.

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing positive growth in revenue and decreasing operating expenses. The company's product portfolio includes treatments for Fabry disease, Pompe disease, and Batten disease, with potential gene therapies in development. The recent approval of Pombiliti and Opfolda in the UK strengthens Amicus' global presence and offers new treatment options for patients with rare diseases.

Amicus Therapeutics: U.K. Approval Expands Global Reach

Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth, Strong Momentum Continued Non-COVID Late-phase And Commercial Manufacturing Revenue Grew by 130.3% Y-o-Y "R" in CRDMO Accelerated to Extend Partnerships with Pharma Clients, Milestone Revenue Approximated US$60 Million Positive Free Cash Flow to Support Sustainable Growth Total Backlog Amounted to US$20,108 Million *        *        * CRDMO Business Model Led Sustainable Long-Term Growth "Follow and Win the Molecule" Strategies Delivered Solid Revenue Increases 621 Total Integrated Projects, Including 46 New Additions 44 Phase III Projects & 22 Commercial Manufacturing (CMO) Projects with Potential for Accelerating Growth "Win-the-Molecule" Strategy Contributed 11 External Projects with Upside Potential Late-phase & Commercial Manufacturing Revenue Increased to RMB3,603.3 Million, Accounting for 42.4% of Total Revenue Global Presence Enhanced and Talent Pool Expanded to Support Business Growth North American and European Markets Maintained Strong Growth Premier Quality System with 30 Successful Global Regulatory Inspections WBS (WuXi Biologics Business System) Deployed to Improve Efficiencies Sufficient Capacity to Start Any Project within 4 Weeks HONG KONG , Aug. 23, 2023 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2023 ("Reporting Period"). 2023 Interim Financial Highlights Revenue: The Group's revenue increased to RMB8,492.0 million with an increase of 17.8% y-o-y.

WuXi Biologics Reports Solid 2023 Interim Results

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry.

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Daphne Quimi - Chief Financial Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Ritu Baral - TD Cowen Eliana Merle - UBS Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Jeff Hung - Morgan Stanley Kristen Kluska - Cantor Fitzgerald Ethan Markowski - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Second Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript

Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.21 per share a year ago.

Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold ® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti ® + Opfolda ® Underway; U.S. and U.K. Approvals Expected 3Q 2023 Reducing 2023 Non-GAAP Operating Expense Guidance to $330M-$350M Non-GAAP Profitability Projected in 2H 2023 Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the second quarter ended June 30, 2023.

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

First Watch Restaurant Group

VersaBank

First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.

3 Top Breakout Stocks to Invest in for Excellent Returns

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2023.

Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023

Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.

Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD)

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

The FDA inspected the WuXi facility this month, and Amicus Therapeutics, Inc. expects approval in the third quarter. Galafold revenue is growing, although the ANDA challenge needs to be resolved.

Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates.

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Daphne Quimi - Chief Financial Officer Andrew Faughnan - Vice President, Investor Relations Conference Call Participants Malcolm Kuno - JP Morgan Ellie Merle - UBS Joseph Schwartz - SVB Securities Athena - Cowen Dae Gon Ha - Stifel Kristen Kluska - Cantor Fitzgerald Shrinatra - Goldman Sachs Jeff Hung - Morgan Stanley Zhiqiang Shu - Berenberg Operator Good morning ladies and gentlemen and welcome to the Amicus Therapeutics first quarter 2023 financial results conference call and webcast. At this time, all participants are in a listen-only mode.

Amicus Therapeutics (FOLD) Q1 2023 Earnings Call Transcript

Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.30 per share a year ago.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Complete; Approval Expected 3Q 2023 European Launch of Pombiliti ® +Opfolda ® Expected 3Q 2023 Non-GAAP Profitability Projected in 2H 2023 Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2023.

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care Conference in Las Vegas, NV on Thursday, May 11, 2023, at 8:40 a.m. PT.

Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Amicus Therapeutics Stock (FOLD)